全文获取类型
收费全文 | 41697篇 |
免费 | 2058篇 |
国内免费 | 259篇 |
专业分类
耳鼻咽喉 | 526篇 |
儿科学 | 694篇 |
妇产科学 | 933篇 |
基础医学 | 5069篇 |
口腔科学 | 1869篇 |
临床医学 | 3051篇 |
内科学 | 11058篇 |
皮肤病学 | 599篇 |
神经病学 | 3848篇 |
特种医学 | 1652篇 |
外国民族医学 | 1篇 |
外科学 | 6285篇 |
综合类 | 190篇 |
一般理论 | 10篇 |
预防医学 | 1991篇 |
眼科学 | 591篇 |
药学 | 2480篇 |
中国医学 | 154篇 |
肿瘤学 | 3013篇 |
出版年
2023年 | 227篇 |
2022年 | 454篇 |
2021年 | 1002篇 |
2020年 | 574篇 |
2019年 | 805篇 |
2018年 | 1025篇 |
2017年 | 713篇 |
2016年 | 859篇 |
2015年 | 976篇 |
2014年 | 1394篇 |
2013年 | 1785篇 |
2012年 | 2845篇 |
2011年 | 3090篇 |
2010年 | 1780篇 |
2009年 | 1602篇 |
2008年 | 2716篇 |
2007年 | 2801篇 |
2006年 | 2616篇 |
2005年 | 2581篇 |
2004年 | 2405篇 |
2003年 | 2083篇 |
2002年 | 1994篇 |
2001年 | 631篇 |
2000年 | 612篇 |
1999年 | 584篇 |
1998年 | 385篇 |
1997年 | 305篇 |
1996年 | 297篇 |
1995年 | 235篇 |
1994年 | 210篇 |
1993年 | 179篇 |
1992年 | 418篇 |
1991年 | 371篇 |
1990年 | 366篇 |
1989年 | 343篇 |
1988年 | 314篇 |
1987年 | 279篇 |
1986年 | 249篇 |
1985年 | 237篇 |
1984年 | 231篇 |
1983年 | 164篇 |
1982年 | 124篇 |
1981年 | 92篇 |
1980年 | 75篇 |
1979年 | 100篇 |
1978年 | 87篇 |
1977年 | 105篇 |
1975年 | 69篇 |
1974年 | 77篇 |
1973年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
Toshihiro Yoshitake Akira Takeda Kensaku Ohki Yuko Inoue Takanori Yamawaki Saori Otsuka Minekatsu Akimoto Mitsuru Nemoto Yasuhito Shimakura Akio Sato 《The Journal of dermatology》2015,42(7):735-738
Finasteride is standard medical treatment for androgenetic alopecia; however, no large studies with 5 years or more of follow up have been performed in Japan. The authors followed Japanese men with androgenetic alopecia treated with finasteride for 5 years to evaluate long‐term treatment efficacy. Of 903 men treated with finasteride (1 mg/day), 801 patients were evaluated over 5 years by modified global photographic assessment. Although the proportion of improvement was high (99.4%), modified global photographic assessment scores after 5 years of treatment were lower in patients with more advanced disease as measured by the modified Norwood–Hamilton scale. After separating patients into “sufficient” and “insufficient” efficacy groups according to the modified global photographic assessment score after 5 years (scores ≥6 and <6, respectively), multivariate analysis showed that independent risk factors of insufficient efficacy were age at start of treatment of 40 years or more (P = 0.021) and classification on the modified Norwood–Hamilton scale (P < 0.001), whereas presence of stress at start of treatment was a negative predictor (P = 0.025). In conclusion, continuous finasteride treatment for 5 years improved androgenetic alopecia with sustained effect among Japanese. Younger age and less advanced disease at start of treatment were the key predictors of higher finasteride efficacy. 相似文献
2.
3.
Angela Mauro Salvatore Mauro Roberto Rega Luigi Martemucci Rita Sottile 《Pediatric dermatology》2019,36(1):e34-e36
Henoch‐Schonlein purpura (HSP) is the most common systemic vasculitis in childhood. There is no consensus about the management for isolated cutaneous manifestations in HSP. We describe a case of HSP presenting with severe skin lesions that did not respond to standard therapy with corticosteroids. The 11‐year‐old child was treated with intravenous immunoglobulins, which induced rapid and persistent resolution of symptomatology. 相似文献
4.
A growing body of data suggests that therapies based on Toll-like receptors (TLR) targeting, in particular TLR4, holds promise in curing autoimmune and inflammatory pathologies still lacking specific treatment, included several rare diseases. While TLR4 activators (agonists) have already found successful clinical application as vaccine adjuvants, the use of TLR4 blockers (antagonists) as antisepsis agents or as agents against inflammatory diseases (including arthritis, multiple sclerosis, neuroinflammations) and cancer is still at a preclinical phase of development. This minireview focuses on recent achievements on the development of TLR4 modulators based on lipid A structure simplification, in particular on compounds having disaccharide or monosaccharide structures. As the TLR4 activity of natural TLR4 ligands (lipopolysaccharide, LPS and its biologically active part, the lipid A) depends on both the structure of endotoxin aggregates in solution and on single-molecule interaction with MD-2 and CD14 receptors, the rational design of TLR4 modulators should in principle take into account both these factors. In the light of the most recent advances in the field, in this minireview we discuss the structure–activity relationship in simplified lipid A analogs, with cationic or anionic amphiphilic structures. 相似文献
5.
6.
7.
Melatonin reduces oxidative stress and improves vascular function in pulmonary hypertensive newborn sheep 下载免费PDF全文
Flavio Torres Alejandro González‐Candia Camilo Montt Germán Ebensperger Magdalena Chubretovic María Serón‐Ferré Roberto V. Reyes Aníbal J. Llanos Emilio A. Herrera 《Journal of pineal research》2015,58(3):362-373
Pulmonary hypertension of the newborn (PHN) constitutes a critical condition with severe cardiovascular and neurological consequences. One of its main causes is hypoxia during gestation, and thus, it is a public health concern in populations living above 2500 m. Although some mechanisms are recognized, the pathophysiological facts that lead to PHN are not fully understood, which explains the lack of an effective treatment. Oxidative stress is one of the proposed mechanisms inducing pulmonary vascular dysfunction and PHN. Therefore, we assessed whether melatonin, a potent antioxidant, improves pulmonary vascular function. Twelve newborn sheep were gestated, born, and raised at 3600 meters. At 3 days old, lambs were catheterized and daily cardiovascular measurements were recorded. Lambs were divided into two groups, one received daily vehicle as control and another received daily melatonin (1 mg/kg/d), for 8 days. At 11 days old, lung tissue and small pulmonary arteries (SPA) were collected. Melatonin decreased pulmonary pressure and resistance for the first 3 days of treatment. Further, melatonin significantly improved the vasodilator function of SPA, enhancing the endothelial‐ and muscular‐dependent pathways. This was associated with an enhanced nitric oxide‐dependent and nitric oxide independent vasodilator components and with increased nitric oxide bioavailability in lung tissue. Further, melatonin reduced the pulmonary oxidative stress markers and increased enzymatic and nonenzymatic antioxidant capacity. Finally, these effects were associated with an increase of lumen diameter and a mild decrease in the wall of the pulmonary arteries. These outcomes support the use of melatonin as an adjuvant in the treatment for PHN. 相似文献
8.
9.
10.
Rahul S. Loungani Marat Fudim Dave Ranney Ajar Kochar Marc D. Samsky Desiree Bonadonna Akinobu Itoh Hiroo Takayama Koji Takeda Daniel Wojdyla Adam D. DeVore Mani Daneshmand 《Journal of cardiac failure》2021,27(3):327-337
BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as a life-saving therapy for patients with cardiovascular collapse, but identifying patients unlikely to benefit remains a challenge.Methods and ResultsWe created the RESCUE registry, a retrospective, observational registry of adult patients treated with VA-ECMO between January 2007 and June 2017 at 3 high-volume centers (Columbia University, Duke University, and Washington University) to describe short-term patient outcomes. In 723 patients treated with VA-ECMO, the most common indications for deployment were postcardiotomy shock (31%), cardiomyopathy (including acute heart failure) (26%), and myocardial infarction (17%). Patients frequently suffered in-hospital complications, including acute renal dysfunction (45%), major bleeding (41%), and infection (33%). Only 40% of patients (n = 290) survived to discharge, with a minority receiving durable cardiac support (left ventricular assist device [n = 48] or heart transplantation [n = 7]). Multivariable regression analysis identified risk factors for mortality on ECMO as older age (odds ratio [OR], 1.26; 95% confidence interval [CI], 1.12–1.42) and female sex (OR, 1.44; 95% CI, 1.02–2.02) and risk factors for mortality after decannulation as higher body mass index (OR 1.17; 95% CI, 1.01-1.35) and major bleeding while on ECMO support (OR, 1.92; 95% CI, 1.23–2.99).ConclusionsDespite contemporary care at high-volume centers, patients treated with VA-ECMO continue to have significant in-hospital morbidity and mortality. The optimization of outcomes will require refinements in patient selection and improvement of care delivery. 相似文献